Novo Nordisk has launched the 7.2 mg injectable form of Wegovy in the United States for obesity treatment. The high-dose version of the GLP-1 agonist is now available to patients, expanding treatment options for obesity management.
Wegovy has become a cornerstone product for Novo Nordisk in the rapidly growing obesity treatment market. The GLP-1 class of drugs has transformed how medical professionals approach weight management, offering patients significant weight loss potential through appetite suppression and improved glucose control.